What is PharmaCann?
Established in 2014, PharmaCann operates at the intersection of biotechnology and consumer wellness. The company is dedicated to the discovery, production, and responsible dispensing of cannabis-related products, aiming to improve patient quality of life through evidence-based methodologies. Headquartered in Chicago, Illinois, PharmaCann has evolved from a regional operator into a significant player in the North American cannabis landscape. Its market position is defined by a focus on the science-based understanding of cannabis, which allows the firm to navigate complex regulatory environments while maintaining a competitive edge in product efficacy and safety. By integrating advanced production techniques with a patient-centric philosophy, PharmaCann serves as a critical link in the modern healthcare supply chain.
How much funding has PharmaCann raised?
PharmaCann has raised a total of $194.9M across 3 funding rounds:
Corporate Investment
$110.4M
Debt
$39.5M
Other Financing Round
$45M
Corporate Investment (2021): $110.4M with participation from The Cronos Group
Debt (2022): $39.5M, investors not publicly disclosed
Other Financing Round (2022): $45M supported by Innovative Industrial Properties
Key Investors in PharmaCann
The Cronos Group
Cronos Group is an innovative global cannabinoid company with international production and distribution across five continents. The company was founded in 2012 and is headquartered in Toronto, Ontario.
Innovative Industrial Properties
Innovative Industrial Properties, Inc. is a self-advised Maryland corporation focused on the acquisition, ownership and management of specialized industrial properties leased to experienced, state-licensed operators for their regulated cannabis facilities.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for PharmaCann?
With the recent infusion of capital, PharmaCann is expected to prioritize the scaling of its production infrastructure and the deepening of its clinical research pipeline. The strategic allocation of these funds will likely focus on enhancing supply chain resilience and expanding market reach into emerging jurisdictions. As the regulatory landscape for cannabis continues to shift, PharmaCann's emphasis on scientific validation and responsible stewardship will be paramount in securing long-term market leadership. Future growth will likely be driven by the commercialization of new therapeutic formulations and the optimization of its existing distribution network, ensuring the company remains at the forefront of the global cannabinoid industry.
See full PharmaCann company page
